Is there a role for liver biopsy in primary sclerosing cholangitis?

Kelly W. Burak, Paul Angulo, Keith Lindor

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

OBJECTIVE: Liver biopsies are performed in patients with primary sclerosing cholangitis (PSC) to stage disease and to rule out coexisting liver disease. The purpose of this study was to examine how often routine liver biopsies provide important information in patients with PSC. METHODS: We reviewed the charts of 138 patients with a cholangiographic diagnosis of PSC to determine whether information from liver biopsy had an impact on clinical management. RESULTS: A total of 30 patients did not have a liver biopsy, whereas 29 patients had a biopsy before cholangiography. In 79 patients the liver biopsy was performed after the diagnosis of PSC was established by cholangiography (median time from cholangiography to liver biopsy, 21 days). In 78 of 79 patients (98.7%) the liver biopsy revealed no atypical findings and did not affect clinical management. In one patient the liver biopsy revealed findings of an overlap syndrome with autoimmune hepatitis, and the patient was treated with corticosteroids and azathioprine. This patient had biochemical features consistent with autoimmune hepatitis. One patient developed a bile leak after liver biopsy, requiring hospitalization (complication rate 0.9%). CONCLUSIONS: Liver biopsies rarely contribute new information that affects the management of patients with PSC. Given the risks of the procedure, liver biopsies for patients with a diagnosis of PSC established by cholangiography may not routinely be necessary.

Original languageEnglish (US)
Pages (from-to)1155-1158
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume98
Issue number5
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Sclerosing Cholangitis
Biopsy
Liver
Cholangiography
Autoimmune Hepatitis
Information Management
Azathioprine
Bile
Liver Diseases
Adrenal Cortex Hormones

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Is there a role for liver biopsy in primary sclerosing cholangitis? / Burak, Kelly W.; Angulo, Paul; Lindor, Keith.

In: American Journal of Gastroenterology, Vol. 98, No. 5, 01.05.2003, p. 1155-1158.

Research output: Contribution to journalArticle

@article{3dacb6c7996b44fd922229c0797616f6,
title = "Is there a role for liver biopsy in primary sclerosing cholangitis?",
abstract = "OBJECTIVE: Liver biopsies are performed in patients with primary sclerosing cholangitis (PSC) to stage disease and to rule out coexisting liver disease. The purpose of this study was to examine how often routine liver biopsies provide important information in patients with PSC. METHODS: We reviewed the charts of 138 patients with a cholangiographic diagnosis of PSC to determine whether information from liver biopsy had an impact on clinical management. RESULTS: A total of 30 patients did not have a liver biopsy, whereas 29 patients had a biopsy before cholangiography. In 79 patients the liver biopsy was performed after the diagnosis of PSC was established by cholangiography (median time from cholangiography to liver biopsy, 21 days). In 78 of 79 patients (98.7{\%}) the liver biopsy revealed no atypical findings and did not affect clinical management. In one patient the liver biopsy revealed findings of an overlap syndrome with autoimmune hepatitis, and the patient was treated with corticosteroids and azathioprine. This patient had biochemical features consistent with autoimmune hepatitis. One patient developed a bile leak after liver biopsy, requiring hospitalization (complication rate 0.9{\%}). CONCLUSIONS: Liver biopsies rarely contribute new information that affects the management of patients with PSC. Given the risks of the procedure, liver biopsies for patients with a diagnosis of PSC established by cholangiography may not routinely be necessary.",
author = "Burak, {Kelly W.} and Paul Angulo and Keith Lindor",
year = "2003",
month = "5",
day = "1",
doi = "10.1111/j.1572-0241.2003.07401.x",
language = "English (US)",
volume = "98",
pages = "1155--1158",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Is there a role for liver biopsy in primary sclerosing cholangitis?

AU - Burak, Kelly W.

AU - Angulo, Paul

AU - Lindor, Keith

PY - 2003/5/1

Y1 - 2003/5/1

N2 - OBJECTIVE: Liver biopsies are performed in patients with primary sclerosing cholangitis (PSC) to stage disease and to rule out coexisting liver disease. The purpose of this study was to examine how often routine liver biopsies provide important information in patients with PSC. METHODS: We reviewed the charts of 138 patients with a cholangiographic diagnosis of PSC to determine whether information from liver biopsy had an impact on clinical management. RESULTS: A total of 30 patients did not have a liver biopsy, whereas 29 patients had a biopsy before cholangiography. In 79 patients the liver biopsy was performed after the diagnosis of PSC was established by cholangiography (median time from cholangiography to liver biopsy, 21 days). In 78 of 79 patients (98.7%) the liver biopsy revealed no atypical findings and did not affect clinical management. In one patient the liver biopsy revealed findings of an overlap syndrome with autoimmune hepatitis, and the patient was treated with corticosteroids and azathioprine. This patient had biochemical features consistent with autoimmune hepatitis. One patient developed a bile leak after liver biopsy, requiring hospitalization (complication rate 0.9%). CONCLUSIONS: Liver biopsies rarely contribute new information that affects the management of patients with PSC. Given the risks of the procedure, liver biopsies for patients with a diagnosis of PSC established by cholangiography may not routinely be necessary.

AB - OBJECTIVE: Liver biopsies are performed in patients with primary sclerosing cholangitis (PSC) to stage disease and to rule out coexisting liver disease. The purpose of this study was to examine how often routine liver biopsies provide important information in patients with PSC. METHODS: We reviewed the charts of 138 patients with a cholangiographic diagnosis of PSC to determine whether information from liver biopsy had an impact on clinical management. RESULTS: A total of 30 patients did not have a liver biopsy, whereas 29 patients had a biopsy before cholangiography. In 79 patients the liver biopsy was performed after the diagnosis of PSC was established by cholangiography (median time from cholangiography to liver biopsy, 21 days). In 78 of 79 patients (98.7%) the liver biopsy revealed no atypical findings and did not affect clinical management. In one patient the liver biopsy revealed findings of an overlap syndrome with autoimmune hepatitis, and the patient was treated with corticosteroids and azathioprine. This patient had biochemical features consistent with autoimmune hepatitis. One patient developed a bile leak after liver biopsy, requiring hospitalization (complication rate 0.9%). CONCLUSIONS: Liver biopsies rarely contribute new information that affects the management of patients with PSC. Given the risks of the procedure, liver biopsies for patients with a diagnosis of PSC established by cholangiography may not routinely be necessary.

UR - http://www.scopus.com/inward/record.url?scp=0038070406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038070406&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2003.07401.x

DO - 10.1111/j.1572-0241.2003.07401.x

M3 - Article

VL - 98

SP - 1155

EP - 1158

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -